Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 4/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30661804 | 1.00 | GPR119 (0.45) | GPR119RIPK1GSK3BMAPK1RORC | |
| SCHEMBL30273301 | 1.00 | GPR119 (0.45) | GPR119RIPK1GSK3BMAPK1RORC | |
| SCHEMBL24238987 | 1.00 | GPR119 (0.45) | GPR119RIPK1GSK3BMAPK1RORC | |
| SCHEMBL22087688 | 1.00 | GPR119 (0.45) | GPR119RIPK1GSK3BMAPK1RORC | |
| SCHEMBL29116091 | 0.88 | DPP4 (0.40) | GPR119MAPK1RORCUSP30 | |
| SCHEMBL27077237 | 0.88 | DPP4 (0.40) | GPR119MAPK1RORCUSP30 | |
| SCHEMBL29892381 | 0.88 | DPP4 (0.40) | GPR119MAPK1RORCUSP30 | |
| SCHEMBL29891801 | 0.88 | DPP4 (0.40) | GPR119MAPK1RORCUSP30 | |
| SCHEMBL15365495 | 0.87 | ESR2 (0.44) | GPR119MAPK1RORCUSP30TACR1 | |
| SCHEMBL30430522 | 0.87 | GPR119 (0.50) | GPR119MAPK1RORCGRM5USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122036605-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2026-05-15 | — | — | CN | disclosed |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | CYTOKINETICS, INC. | 2024-02-29 | — | — | US | disclosed |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2023-11-07 | — | — | US | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | UNIV OREGON HEALTH & SCIENCE (US) | 2023-06-08 | — | — | US | disclosed |
| CN-115996908-A | Antagonists of GPR39 proteins | 俄勒冈健康科学大学 | 2023-04-21 | — | — | CN | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LTD (GB) | 2022-02-03 | — | — | US | disclosed |
| CN-113365696-A | Pharmaceutical compounds and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2021-09-07 | — | — | CN | disclosed |
| CN-112135818-A | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin-specific protease 19(USP19) | 阿尔麦克探索有限公司 | 2020-12-25 | — | — | CN | disclosed |
| EP-3746432-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | Almac Discovery Limited (GB) | 2020-12-09 | — | — | EP | disclosed |
| WO-2020115501-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2020-06-11 | — | — | WO | disclosed |
| WO-2019150119-A1 | 4-HYDROXYPIPERIDINE DERIVATIVES AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | ALMAC DISCOVERY LIMITED (GB) | 2019-08-08 | — | — | WO | disclosed |
| EP-3057963-B1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INT (DE) | 2019-06-19 | — | — | EP | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| US-9233953-B2 | Derivatives of 4-(piperazinylcarbonyl)thiane-1, 1-dione which inhibit GlyT1 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-01-12 | — | — | US | disclosed |
| WO-2015055698-A1 | PIPERAZINE DERIVATIVES AND THE USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-23 | — | — | WO | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105397-A1 | Piperazine derivatives and the use thereof as medicament | SLC6A7, SLC7A11, SLC7A1 | GPR119 449/4885RIPK1 4222/4885GSK3B 3668/4885 |
| US-20220033397-A1 | PHARMACEUTICAL COMPOUNDS AND THEIR USE AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) | USP19, USP16, USP18 | GPR119 23/4885RIPK1 1003/4885GSK3B 1054/4885 |
| US-20230174484-A1 | ANTAGONISTS OF GPR39 PROTEIN | GPR39, GPR139, GPR119 | GPR119 3/4885RIPK1 2239/4885GSK3B 4078/4885 |
| US-20240067631-A1 | PYRAZOLE DERIVATIVES USEFUL AS NAMPT MODULATORS | NAMPT, NNT, NAPRT | GPR119 213/4885RIPK1 1237/4885GSK3B 1801/4885 |
| US-11807646-B2 | 4-hydroxypiperidine derivatives and their use as inhibitors of ubiquitin specific protease 19 (USP19) | USP19, USP16, USP18 | GPR119 55/4885RIPK1 1869/4885GSK3B 1532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.